948.45
price down icon2.72%   -26.51
after-market After Hours: 949.97 1.52 +0.16%
loading
Lilly Eli Co stock is traded at $948.45, with a volume of 3.24M. It is down -2.72% in the last 24 hours and down -0.51% over the past month. Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$974.96
Open:
$974.07
24h Volume:
3.24M
Relative Volume:
1.00
Market Cap:
$845.77B
Revenue:
$72.25B
Net Income/Loss:
$25.28B
P/E Ratio:
34.14
EPS:
27.781
Net Cash Flow:
$10.37B
1W Performance:
-1.54%
1M Performance:
-0.51%
6M Performance:
+2.61%
1Y Performance:
+26.22%
1-Day Range:
Value
$947.51
$980.00
1-Week Range:
Value
$947.51
$996.49
52-Week Range:
Value
$623.78
$1,133.95

Lilly Eli Co Stock (LLY) Company Profile

Name
Name
Lilly Eli Co
Name
Phone
(317) 276-2000
Name
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Name
Employee
50,000
Name
Twitter
@LillyPad
Name
Next Earnings Date
2026-04-30
Name
Latest SEC Filings
Name
LLY's Discussions on Twitter

Compare LLY vs JNJ, ABBV, AZN, NVS

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
LLY icon
LLY
Lilly Eli Co
948.45 845.77B 72.25B 25.28B 10.37B 27.78
JNJ icon
JNJ
Johnson Johnson
221.32 532.77B 96.36B 21.04B 17.80B 8.6488
ABBV icon
ABBV
Abbvie Inc
201.55 356.49B 62.82B 3.60B 19.98B 2.0274
AZN icon
AZN
Astrazeneca Plc
182.85 283.57B 60.48B 10.40B 8.05B 3.3297
NVS icon
NVS
Novartis Ag Adr
146.03 278.64B 54.66B 13.58B 16.05B 7.0171

Lilly Eli Co Stock (LLY) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-17-26 Downgrade HSBC Securities Hold → Reduce
Feb-25-26 Initiated RBC Capital Mkts Outperform
Feb-20-26 Initiated Barclays Overweight
Jan-07-26 Resumed UBS Buy
Dec-16-25 Upgrade Daiwa Securities Neutral → Buy
Dec-15-25 Reiterated BofA Securities Buy
Dec-15-25 Reiterated Goldman Buy
Nov-13-25 Initiated Scotiabank Sector Outperform
Nov-10-25 Upgrade Leerink Partners Market Perform → Outperform
Oct-20-25 Reiterated BMO Capital Markets Outperform
Oct-14-25 Upgrade Erste Group Hold → Buy
Sep-17-25 Downgrade Berenberg Buy → Hold
Aug-27-25 Upgrade HSBC Securities Reduce → Hold
Aug-18-25 Downgrade Daiwa Securities Outperform → Neutral
Aug-07-25 Downgrade Leerink Partners Outperform → Market Perform
Jun-05-25 Downgrade Erste Group Buy → Hold
Apr-28-25 Downgrade HSBC Securities Buy → Reduce
Apr-22-25 Initiated Cantor Fitzgerald Overweight
Dec-10-24 Resumed BofA Securities Buy
Nov-15-24 Initiated Wolfe Research Outperform
Oct-17-24 Initiated Bernstein Outperform
Sep-13-24 Resumed Citigroup Buy
Aug-12-24 Upgrade Deutsche Bank Hold → Buy
Feb-21-24 Downgrade DZ Bank Buy → Hold
Feb-16-24 Reiterated Morgan Stanley Overweight
Dec-21-23 Downgrade Daiwa Securities Buy → Outperform
Nov-09-23 Initiated Deutsche Bank Hold
Oct-20-23 Resumed UBS Buy
Aug-09-23 Upgrade Jefferies Hold → Buy
Jul-26-23 Reiterated Citigroup Buy
Jul-14-23 Initiated HSBC Securities Buy
May-24-23 Reiterated BofA Securities Buy
May-24-23 Reiterated UBS Buy
Mar-13-23 Upgrade Wells Fargo Equal Weight → Overweight
Mar-06-23 Initiated Jefferies Hold
Feb-15-23 Downgrade Societe Generale Hold → Sell
Nov-18-22 Initiated Credit Suisse Outperform
Sep-22-22 Upgrade UBS Neutral → Buy
May-23-22 Initiated SVB Leerink Outperform
Apr-06-22 Resumed Morgan Stanley Overweight
Mar-10-22 Initiated Daiwa Securities Outperform
Jan-21-22 Upgrade DZ Bank Hold → Buy
Jan-03-22 Reiterated Bernstein Mkt Perform
Dec-17-21 Initiated Goldman Neutral
Dec-16-21 Reiterated BMO Capital Markets Outperform
Dec-16-21 Reiterated BofA Securities Buy
Dec-09-21 Resumed Wells Fargo Equal Weight
Nov-19-21 Initiated BMO Capital Markets Outperform
Oct-11-21 Upgrade Berenberg Hold → Buy
Sep-29-21 Upgrade Citigroup Neutral → Buy
Aug-05-21 Upgrade DZ Bank Hold → Buy
Jul-27-21 Resumed Truist Buy
Jun-24-21 Reiterated Cantor Fitzgerald Overweight
Jan-19-21 Upgrade Mizuho Neutral → Buy
Dec-10-20 Upgrade Wolfe Research Peer Perform → Outperform
Nov-10-20 Resumed Bernstein Mkt Perform
Sep-29-20 Initiated Berenberg Hold
Sep-03-20 Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-16-20 Upgrade Guggenheim Neutral → Buy
Apr-21-20 Downgrade UBS Buy → Neutral
Apr-09-20 Downgrade Morgan Stanley Overweight → Equal-Weight
Feb-06-20 Initiated Mizuho Neutral
Dec-18-19 Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-17-19 Resumed BofA/Merrill Buy
May-28-19 Initiated Goldman Buy
Apr-24-19 Upgrade Edward Jones Hold → Buy
Apr-11-19 Downgrade Guggenheim Buy → Neutral
Mar-12-19 Initiated JP Morgan Overweight
Jan-23-19 Initiated UBS Buy
Nov-26-18 Downgrade Citigroup Buy → Neutral
Oct-31-18 Upgrade Credit Suisse Underperform → Neutral
Oct-09-18 Initiated Guggenheim Buy
Oct-01-18 Reiterated SunTrust Buy
Sep-26-18 Resumed JP Morgan Overweight
View All

Lilly Eli Co Stock (LLY) Latest News

pulisher
10:57 AM

Eli Lilly & Co. stock (US5324571083): Obesity and diabetes growth drive investor focus - AD HOC NEWS

10:57 AM
pulisher
09:21 AM

Insider Frenzy at JPMorgan, Chevron, Eli Lilly, Berkshire, Strategy - TipRanks

09:21 AM
pulisher
06:46 AM

Is This News From Novo Nordisk a Warning for Eli Lilly Shareholders? - AOL.com

06:46 AM
pulisher
06:17 AM

Jean Santana Appointed as Senior Director – Global People Strategy, Manufacturing & Quality at Eli Lilly and Company - hrtoday.in

06:17 AM
pulisher
06:05 AM

LLY6388974 Bond Price and Chart — FINRA:LLY6388974 - TradingView

06:05 AM
pulisher
06:05 AM

Is This News From Novo Nordisk a Warning for Eli Lilly Shareholders? - The Motley Fool

06:05 AM
pulisher
May 08, 2026

Eli Lilly Stock Hits Bottleneck After 400% Surge in Five Years, Novo Nordisk Poised for a Comeback with 4% Dividend Yield - NAI500

May 08, 2026
pulisher
May 08, 2026

Lilly's Next Obesity Drug Is So Powerful It's Already Getting Copied - Investor's Business Daily

May 08, 2026
pulisher
May 08, 2026

GLP-1 battle heats up between Eli Lilly and Novo Nordisk - Yahoo Finance UK

May 08, 2026
pulisher
May 08, 2026

Lilly to invest extra $4.5B across Indiana manufacturing - Manufacturing Dive

May 08, 2026
pulisher
May 08, 2026

Parkland board hesitates on tax abatement for Eli Lilly - Lehigh Valley Press

May 08, 2026
pulisher
May 08, 2026

Omada Health (OMDA) Q1 2026 Earnings Transcript - The Globe and Mail

May 08, 2026
pulisher
May 08, 2026

Lilly's obesity pill tops 7,000 prescriptions in fourth week, signals modest uptake - Reuters

May 08, 2026
pulisher
May 08, 2026

Will Eli Lilly Be the First $2 Trillion Healthcare Stock? 3 Catalysts That Could Get It There. - Yahoo Finance

May 08, 2026
pulisher
May 08, 2026

Eli Lilly and Company 8-K Filing May 2026 – SEC Document Details, Registered Securities & Company Information - Minichart

May 08, 2026
pulisher
May 08, 2026

Lilly invests $4.5B in Indiana manufacturing, opens doors of 1st genetic medicine site - PharmaLive

May 08, 2026
pulisher
May 08, 2026

Here is Why Eli Lilly (LLY) is One of the Best Stocks to Buy for the Next 15 Years - Insider Monkey

May 08, 2026
pulisher
May 08, 2026

Eli Lilly (LLY) issues $9.0B multi‑tranche notes; Centessa redemption clause included - Stock Titan

May 08, 2026
pulisher
May 08, 2026

Eli Lilly Stock a Strong Buy in 2026 as Mounjaro, Zepbound Demand Fuels Blowout Growth and Analyst Upside - International Business Times Australia

May 08, 2026
pulisher
May 08, 2026

Eli Lilly's (NYSE:LLY) Earnings Are Weaker Than They Seem - Yahoo Finance

May 08, 2026
pulisher
May 07, 2026

Major Legacy Investor Makes a Powerful Move in Eli Lilly Stock - TipRanks

May 07, 2026
pulisher
May 07, 2026

Eli Lilly Shareholders Back Board, Maintain Governance Structure - TipRanks

May 07, 2026
pulisher
May 07, 2026

Omada Health joins Eli Lilly employer weight loss program - Investing.com

May 07, 2026
pulisher
May 07, 2026

Eli Lilly revives dollar market with $9bn M&A financing - GlobalCapital

May 07, 2026
pulisher
May 07, 2026

Declaration of Voting Results by Eli Lilly - marketscreener.com

May 07, 2026
pulisher
May 07, 2026

Eli Lilly (NYSE: LLY) investors back board, keep supermajority rules - Stock Titan

May 07, 2026
pulisher
May 07, 2026

44% of surveyed GLP-1 patients pay over $250 a month as Omada adds Lilly channel - Stock Titan

May 07, 2026
pulisher
May 07, 2026

Eli Lilly & Co. stock underperforms Thursday when compared to competitors - MarketWatch

May 07, 2026
pulisher
May 07, 2026

Lilly Endowment Inc. sells Eli Lilly (NYSE:LLY) stock worth $15.75 million - Investing.com

May 07, 2026
pulisher
May 07, 2026

Omada Health Joins Lilly Employer Connect, Expanding Its Access Pathways for GLP-1 Care as Patients Seek More Lifestyle Support - Yahoo Finance UK

May 07, 2026
pulisher
May 07, 2026

Lilly Endowment trims Eli Lilly (LLY) stake with 15,828-share open sale - Stock Titan

May 07, 2026
pulisher
May 07, 2026

Forget Eli Lilly: These 2 Stocks Have More Upside - The Motley Fool

May 07, 2026
pulisher
May 07, 2026

What the FDA's Latest Proposal Means for Lilly, Novo, and Hims - MarketBeat

May 07, 2026
pulisher
May 07, 2026

Is Eli Lilly and Company (LLY) One of the Best Strong Buy Growth Stocks to Buy Right Now? - Insider Monkey

May 07, 2026
pulisher
May 07, 2026

Cantor Fitzgerald Lifts PT on Eli Lilly and Company (LLY) on Q1 Earnings Call - Insider Monkey

May 07, 2026
pulisher
May 07, 2026

Eli Lilly Now Has the World's Best-Selling Drug -- But Does That Make the Stock a No-Brainer Buy? - Yahoo Finance

May 07, 2026
pulisher
May 07, 2026

Lilly and Regeneron Advance Obesity Combo Bet as Key Tirzepatide Trial Reaches Completion - TipRanks

May 07, 2026
pulisher
May 07, 2026

Novo (NVO) and Lilly (LLY) Stocks Jump as Weight-Loss Pills Reveal Monster Market Potential - TipRanks

May 07, 2026
pulisher
May 07, 2026

Lilly announces additional $4.5B investment at LEAP District manufacturing site - dailyjournal.net

May 07, 2026
pulisher
May 07, 2026

Lilly Invests $4.5B to Indiana Manufacturing Site - PharmTech.com

May 07, 2026
pulisher
May 07, 2026

Novo and Lilly gain on signs weight-loss pills could expand the market - Reuters

May 07, 2026
pulisher
May 07, 2026

Wolfe Research Says Market Reaction on Eli Lilly (LLY) Foundayo Report Appears Overdone - Insider Monkey

May 07, 2026
pulisher
May 07, 2026

Rothschild & Co Redburn Adjusts Price Target on Eli Lilly to $900 From $880 - Moomoo

May 07, 2026
pulisher
May 07, 2026

Eli Lilly’s Mounjaro Becomes World’s Top-Selling Drug - The Business of Fashion

May 07, 2026
pulisher
May 07, 2026

Lilly announces another $4.5 billion investment, opens first LEAP facility - reporter.net

May 07, 2026
pulisher
May 07, 2026

Eli Lilly: Additional $4.5bn to support its industrial scale-up - marketscreener.com

May 07, 2026
pulisher
May 07, 2026

America's Weight-Loss Drug Boom Is Going Global -- Heard on the Street -- WSJ - Moomoo

May 07, 2026
pulisher
May 07, 2026

The Zacks Analyst Blog Highlights Eli Lilly, Western Digital, Vertiv Holdings and AgEagle - Yahoo Finance Singapore

May 07, 2026
pulisher
May 07, 2026

Eli Lilly To Invest $4.5 Billion More In Indiana Manufacturing Sites - Benzinga

May 07, 2026
pulisher
May 07, 2026

My Top Obesity Stock to Buy and Hold - AOL.com

May 07, 2026
pulisher
May 07, 2026

Lilly grants Korean biotech 1STBIO access to proprietary AI drug discovery models - koreabiomed.com

May 07, 2026

Lilly Eli Co Stock (LLY) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
JNJ JNJ
$221.32
price down icon 0.53%
$201.55
price down icon 0.57%
AZN AZN
$182.85
price up icon 0.18%
NVS NVS
$146.03
price up icon 0.44%
MRK MRK
$111.38
price down icon 0.82%
Cap:     |  Volume (24h):